Cambrex completes $50 million investment in large-scale API manufacturing and storage

The company's investment reflects the strong market demand for small molecule APIs.

The new 7,500 sq. ft. multi-purpose manufacturing facility will initially add a total of 70 m3 of glass-lined and Hastelloy reactors ranging in size from 7 m3 to 16 m3, along with 6m 2 Hastelloy agitated filter dryers to provide a flexible, multi-purpose configuration, and will be capable of handling potent APIs at an Occupational Exposure Limit (OEL) of down to 1 μg/m3. The facility complements the three existing large scale manufacturing facilities at the Charles City site.

The 36,000 sq. ft. cGMP warehouse provides general cGMP storage for 2,720 pallets and segregated 2–8°C refrigerated storage for 360 pallet spaces and features Distributed Control System monitoring and control for temperature and humidity. The facility employs a barcode system for automated bin location and has a dedicated sampling room with appropriate extraction and handling for flammable materials.

In addition, a further 7,500 sq. ft. manufacturing shell has been constructed, which will be fitted out to customer specification.

“There is high demand for US based suppliers with large scale cGMP contract manufacturing capacity and world class quality systems,” commented Steve Klosk, CEO of Cambrex. He added: “We have invested over $125 million at the Charles City site since we acquired it in 1991 and believe that this expansion, combined with a very talented and experienced team, provides an ongoing foundation for our customers’ small molecule product manufacturing needs while supporting our goal of bringing our customers’ products to market quickly.”